02:00 PM EDT, 03/27/2024 (MT Newswires) -- Aura Biosciences ( AURA ) shares were up more than 2% in recent Wednesday trading after the clinical-stage biotechnology company reported its Q4 results.

Earlier, the company booked a Q4 net loss of $22.1 million, compared with a loss of $16.6 million a year earlier.

Analysts polled by Capital IQ expected a net loss of $19.5 million.

As expected, no revenue for the quarter ended Dec. 31 was reported.

As of Dec. 31, the company said it had $226.2 million in cash and cash equivalents and marketable securities, and expected it could fund operations through the second half of 2026.

Price: 7.82, Change: +0.18, Percent Change: +2.42